Testosterone Decanoate
A long-chain (10-carbon) ester of testosterone best known as one of the four components of Sustanon. As a standalone raw ester it is uncommon, but its slow release makes it a component of choice in blends and some long-acting testosterone preparations. Effects are identical to any testosterone preparation once the ester is cleaved; the decanoate chain simply stretches the release window.
01 Overview
Testosterone decanoate is testosterone esterified with decanoic (capric) acid at the 17-beta hydroxyl. The long, lipophilic decanoate chain slows release from the intramuscular depot, giving a duration between cypionate and undecanoate. It is rarely sold as a solo raw ester; almost all human exposure has come through the multi-ester blend Sustanon 250, where decanoate provides the slow tail of the release curve.
Because the parent hormone is testosterone, the effect and side-effect profile is that of testosterone itself once esterase enzymes liberate the free hormone. The only practical differences versus shorter esters are dosing frequency and the time to reach steady state. Standalone pharmacokinetic and efficacy data specific to the decanoate ester are limited, so ratings here reflect the well-characterised parent hormone tempered by thin ester-specific evidence.
02 Mechanism
After intramuscular injection the decanoate ester is slowly hydrolysed by serum esterases to release free testosterone, which binds the androgen receptor in muscle and other tissues to drive anabolic and androgenic signalling. A fraction aromatises to estradiol and is 5-alpha-reduced to DHT.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| TRT-equivalent | 75–125 mg/wk | IM | As part of a blend; testosterone-equivalent replacement dosing. |
| Common | 300–500 mg/wk | IM | Testosterone-equivalent; typically injected once or twice weekly. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased lean massDriven by the released testosterone; dose-dependent hypertrophy well established for the parent hormone. | +3-6 kg over a cycle | Clinical | |
| Increased strengthAndrogen-receptor-mediated gains in maximal force output. | meaningful | Clinical | |
| Stable blood levelsLong ester smooths peaks and troughs compared with shorter esters, reducing injection frequency. | Observational | ||
| Improved libido and moodRestoration or elevation of testosterone typically improves libido and wellbeing at physiologic-to-supraphysiologic levels. | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HPTA suppressionExogenous testosterone suppresses LH/FSH, shutting down endogenous production and spermatogenesis. | Severe | Universal | Clinical | |
| Estrogenic effectsAromatisation to estradiol can cause gynecomastia, water retention and elevated blood pressure. | Moderate | Common at higher doses | Clinical | |
| ErythrocytosisRaised haematocrit increases blood viscosity and thrombotic risk. | Moderate | Dose-dependent | Clinical |